Home LiteratureArticle Details
PMID: 8257125 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.

Antimicrobial agents and chemotherapy ·Vol. 37 ·No. 10 ·1993-10-00 ·Pages 2069-73

Whitman MS, Pitsakis PG, Zausner A, Livornese LL, Osborne AJ, Johnson CC, Levison ME

Abstract

We compared ciprofloxacin, rifampin, and gentamicin treatments, alone and in combination, for 5 days in the therapy of experimental aortic valve endocarditis in rats caused by a clinical isolate of vancomycin-resistant Enterococcus faecium. The MICs and MBCs of vancomycin, ciprofloxacin, rifampin, and gentamicin were 250 and > 1,000, 3.1 and 6.3, 0.098 and 1.6, and 12.5 and > 50 micrograms/ml, respectively. Infected rats were sacrificed after completing 5 days of therapy. Additional rats within each treatment group were followed for 5 days beyond the last dose of antibiotic therapy. Although survivals in the different groups were not significantly different after 5 days of therapy, survival was significantly better 5 days beyond the last dose of antibiotic therapy in rats treated with rifampin-containing regimens. The combination of ciprofloxacin and gentamicin was bactericidal in vitro and in vegetations from rats with enterococcal endocarditis. Rifampin alone was similarly bactericidal in vivo, but it was not significantly better than rifampin in combination with other antibiotics. Subpopulations resistant to rifampin, but not ciprofloxacin, were detected in the inoculum and in most vegetations during therapy. However, the combination of ciprofloxacin plus both gentamicin and rifampin reduced both the rifampin-susceptible and -resistant population in vegetations of 9 of 10 animals below the level of detection after 5 days of therapy. Nevertheless, a residual enterococcal population apparently remained in numbers of < 2 log10 CFU/g after 5 days of therapy, which resulted in relapse. Perhaps a longer course of therapy would have eliminated this residual population and improved efficacy.

MeSH Terms
Ampicillin Resistance Animals Ciprofloxacin/blood,pharmacology Disease Models, Animal Drug Resistance, Microbial Drug Therapy, Combination/pharmacology Endocarditis, Bacterial/drug therapy,microbiology Enterococcus faecalis/drug effects,physiology Gentamicins/blood,pharmacology Gram-Positive Bacterial Infections Male Microbial Sensitivity Tests Rats Rats, Sprague-Dawley Rifampin/blood,pharmacology Vancomycin/pharmacology
Chemicals
Gentamicins Ciprofloxacin Vancomycin Rifampin
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Whitman M S
Medical College of Pennsylvania, Philadelphia 19129.
Pitsakis P G
Zausner A
Livornese L L
Osborne A J
Johnson C C
Levison M E
References (18)
18 references, click to expand
  1. Plasmid-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium.
    N Engl J Med. 1988 Jul 21;319(3):157-61 PMID: 2968517
  2. Recovery of resistant enterococci during vancomycin prophylaxis.
    J Clin Microbiol. 1988 Jun;26(6):1216-8 PMID: 3384933
  3. High-level penicillin resistance among isolates of enterococci. Implications for treatment of enterococcal infections.
    Ann Intern Med. 1989 Apr 1;110(7):515-20 PMID: 2923386
  4. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy.
    Antimicrob Agents Chemother. 1989 Jan;33(1):71-7 PMID: 2496659
  5. Inducible, transferable resistance to vancomycin in Enterococcus faecalis A256.
    Antimicrob Agents Chemother. 1989 Feb;33(2):198-203 PMID: 2497704
  6. Bacterial resistance to quinolones: mechanisms and clinical importance.
    Rev Infect Dis. 1989 Jul-Aug;11 Suppl 5:S960-8 PMID: 2549610
  7. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
    Antimicrob Agents Chemother. 1989 Aug;33(8):1184-7 PMID: 2802547
  8. Synergistic bactericidal activity of rat serum with vancomycin against enterococci.
    J Infect Dis. 1991 Jun;163(6):1358-61 PMID: 1903800
  9. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers.
    Ann Intern Med. 1992 Jul 15;117(2):112-6 PMID: 1605425
  10. Antibiotic synergism in enterococcal endocarditis.
    J Lab Clin Med. 1976 Jul;88(1):132-41 PMID: 819602
  11. Rat model of experimental endocarditis.
    Infect Immun. 1978 Mar;19(3):915-8 PMID: 417032
  12. Transferable beta-lactamase. A new mechanism for in vitro penicillin resistance in Streptococcus faecalis.
    J Clin Invest. 1983 Sep;72(3):1168-71 PMID: 6411768
  13. Therapeutic potential of rifampin in enterococcal infections.
    Rev Infect Dis. 1983 Jul-Aug;5 Suppl 3:S528-32 PMID: 6415781
  14. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin.
    J Gen Microbiol. 1985 Aug;131(8):1933-40 PMID: 3850924
  15. beta-Lactamase production in experimental endocarditis due to aminoglycoside-resistant Streptococcus faecalis.
    J Infect Dis. 1987 Jun;155(6):1226-32 PMID: 3106510
  16. Identification of Streptococcus faecalis and Streptococcus faecium and susceptibility studies with newly developed antimicrobial agents.
    J Clin Microbiol. 1987 May;25(5):787-90 PMID: 3108309
  17. Vancomycin-resistant enterococci.
    Lancet. 1988 Jan 2-9;1(8575-6):57-8 PMID: 2891921
  18. Antimicrobial treatment of infective endocarditis due to viridans streptococci, enterococci, and staphylococci.
    JAMA. 1989 Mar 10;261(10):1471-7 PMID: 2645447
Article Info
Journal
Antimicrobial agents and chemotherapy
Abbr.
Antimicrob Agents Chemother
ISSN
0066-4804
Published
1993-10-00
Pages
2069-73
Language
English
Region
United States
NLM ID
0315061
PMCID
PMC192230
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com